Trial Profile
A Phase IV, prospective, open label multicentre study of Raptiva 1mg/kg/week by subcutaneous injection in adults with moderate to severe chronic plaque psoriasis who have failed previous biologic therapy with etanercept.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jun 2011
Price :
$35
*
At a glance
- Drugs Efalizumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Merck Serono
- 21 Jun 2011 New trial record